Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27050968 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL31465140 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL14286742 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL8024923 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL15935504 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL13169264 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL7873800 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL5308716 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL17725159 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 | |
| SCHEMBL7875756 | 1.00 | TSHR (0.39) | TSHRSPHK1ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025021034-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | VISIRNA THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2025-01-30 | — | — | WO | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | CUREVAC AG (DE) | 2020-01-16 | — | — | US | disclosed |
| US-9125922-B2 | Phosphate esters of gyrase and topoisomerase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-9125922-B2 | Phosphate esters of gyrase and topoisomerase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | SPERO THERAPEUTICS, INC. | 2013-06-20 | — | — | US | disclosed |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | SPERO THERAPEUTICS, INC. | 2013-06-20 | — | — | US | disclosed |
| WO-2012177707-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20110117569-A1 | POLYMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND PROCESSES FOR PREPARING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-7897346-B2 | Polyamide nucleic acid derivatives and agents, and processes for preparing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100029903-A1 | Polypeptide Protracting Tags | NOVO NORDISK A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20100022016-A1 | POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS, AND PROCESSES FOR PREPARING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20070280929-A1 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | CUREVAC GMBH (DE) | 2007-12-06 | — | — | US | disclosed |
| US-7241882-B2 | Polyamide nucleic acid derivatives, and agents, and processes for preparing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| WO-2007068718-A1 | POLYPEPTIDE PROTRACTING TAGS | NOVO NORDISK A/S (DK) | 2007-06-21 | — | — | WO | disclosed |
| US-6472521-B1 | Oligonucleotides for the inhibition of human eg5 expression | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | TSHR 4636/4885SPHK1 2922/4885ZDHHC20 2400/4885 |
| US-20070280929-A1 | ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID | TLR5, TLR9, TLR7 | TSHR 3362/4885SPHK1 1353/4885ZDHHC20 1196/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | TSHR 4626/4885SPHK1 2901/4885ZDHHC20 2394/4885 |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | TSHR 4530/4885SPHK1 2329/4885ZDHHC20 3773/4885 |
| US-20100029903-A1 | Polypeptide Protracting Tags | LAS1L, SEC16A, PHAX | TSHR 849/4885SPHK1 4727/4885ZDHHC20 1400/4885 |
| US-20200016264-A1 | NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | TLR9, TLR3, TLR5 | TSHR 3152/4885SPHK1 1301/4885ZDHHC20 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.